Invest1 publisher2 min readPublished
BCB Bancorp sells stock at 47% below book to clear $306m of problem loans
Thomas O'Brien is spending a discounted $98 million stock sale to clear $306 million of BCB Bancorp's worst credits in a single quarter, and the loss that produces runs to $136.1 million at the top end.
The Investor · Invest desk
What happened
- BCB Bancorp priced 12.65 million new common shares at $7.75, a 47% discount to the $14.73 tangible book value per share it reported at June 30, raising proceeds of nearly $100 million.
- The proceeds fund the sale of $210 million of commercial loans, including commercial real estate, and the reclassification of $96 million more, among them the bank's entire cannabis portfolio, as available-for-sale.
- The Bayonne, New Jersey lender told investors the resulting third-quarter loss will likely land between $126.2 million and $136.1 million.
- Brean Capital's Christopher Marinac, who called the offering large and dilutive, expects total criticized loans to fall to $70 million at year-end from $380 million on June 30.
- No loan buyer has signed a binding commitment, though BCB said it has lined up multiple buyers and expects the transactions to close before the third quarter ends.
Compiled by The InvestorSomething wrong?How this is made
Why it matters
- cost Existing holders pay on both sides of the trade: 12.65 million shares issued at 47% below book, and roughly $33 million of the midpoint loss that the raise does not fund comes out of capital already on the balance sheet.
- contradiction Two analysts called the offering dilutive and the shares still rose about 1.5% in the week after, so the market is pricing the cleanup as worth more than the dilution it costs.
- precedent Marinac says the actions put BCB in position to be sold in early to mid 2027.
- constraint Marking the whole cannabis book for sale ends that line of lending at BCB, and with it the asset class whose real estate write-down produced the bank's $12 million loss in the fourth quarter of 2025.
Work backwards from the ratio and the size of the bank falls out. The $72 million of nonaccrual loans that BCB reported at 2.37 percent of total loans on June 30 [6] implies a book of roughly $3.04 billion [5]. On that base, the $380 million of criticized loans was about 12.5 percent of everything BCB had lent [6], and the $306 million now being sold or marked is about 10 percent [1][7].
Brean Capital's Christopher Marinac put criticized loans at $70 million by year-end, a reduction of $310 million from the June 30 figure [11][8]. The $306 million moving this quarter accounts for nearly all of that. The midpoint of the loss guidance, $131.15 million, works out to about 43 cents for every dollar of the $306 million [3][9]. BCB did not break out the components of the guidance. That 43 cents blends the discount on the $210 million loan sale, the fair-value mark on the $96 million reclassified, and whatever else lands in the quarter [3][4].
The raise does not cover the loss. Selling 12.65 million shares at $7.75 brings in $98.0 million gross [2], about $33 million less than the midpoint [4]. "While we anticipate a difficult financial result this quarter," O'Brien said in a press release, "I believe that outcome is consistent with our commitment to work through the credit portfolios and put transparent, actionable solutions in place promptly" [9].
BCB lost $12 million in the fourth quarter of 2025 on a write-down of cannabis-related real estate and chargeoffs in its commercial-and-industrial book [13]. It lost $14.8 million in the second quarter of 2026, driven largely by a $19 million credit provision [14]. BCB lost $26.8 million across the two quarters [11], and still had $380 million of criticized loans on the balance sheet at June 30 [11]. Piper Sandler's Justin Crowley, who called the stock sale "highly dilutive" [7], wrote that "Though aggressive and costly, this is frankly the price to be paid for moving quickly as opposed to letting credit issues and market uncertainty linger" [8].
O'Brien has orchestrated sales of several ailing banks after nursing them back to health [17]. BCB's nonaccrual ratio was about 2.55 times the industry-wide average of 0.93 percent [10][6]. That average does not show how many banks carry concentrations like BCB's.
The test is whether the $210 million closes at the marks. If the bids come in lower, the loss runs past the top of the range; if they close and the fourth quarter still needs a provision, the marks were set to what $98 million could pay for.
What to watch
- The year-end criticized-loan figure: anything above $70 million means the sale moved less of the book than Marinac modelled.
- Whether BCB returns for more equity once the loan trades settle and the fourth-quarter provision is set.
- Whether the cannabis loans find a buyer at all, or sit in available-for-sale collecting repeat marks.